Free Trial Information
BioCentury | Mar 18, 2010
Distillery Therapeutics

Indication: Cancer

...includes synthesizing polymer conjugates of the compounds to improve their tumor delivery and photoactivation properties. Light Sciences Oncology Inc.'s...
Read More
BioCentury | Mar 8, 2010
Clinical News

Aptocine talaporfin sodium: Completed Phase III enrollment

...296 and 394 events, respectively. Light Sciences has an SPA from FDA for the trial. Light Sciences Oncology Inc....
Read More
BioCentury | Aug 24, 2009
Clinical News

Aptocine talaporfin sodium: Phase II started

...IV Aptocine followed by 100 J/cm of light delivered for 83 minutes in 40 patients. Light Sciences Oncology Inc....
Read More
BioCentury | Aug 17, 2009
Clinical News

Aptocine talaporfin sodium: Phase I started

...of light in 18-24 patients ages 18-34 with PN tumors that are not surgically resectable. Light Sciences Oncology Inc....
Read More
BioCentury | Dec 8, 2008
Clinical News

Litx: Completed Phase III enrollment

...of care treatments including radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and percutaneous ethanol injection (PEI). Light Sciences Oncology Inc....
Read More
BioCentury | Jul 16, 2008
Financial News

Light Sciences raises $40.1 million

Light Sciences Oncology (Bellevue, Wash.) raised $40.1 million in a series C round. Investors were not disclosed. Leerink acted as placement agent and financial advisor. Light Sciences is developing Light Infusion Therapy ( Litx ), a...
Read More
BioCentury | Jul 14, 2008
Clinical News

Litx: Phase IIa start

...This quarter, Light Sciences will begin an Australian Phase IIa trial in 40 patients. Light Sciences Oncology Inc....
Read More
BioCentury | Jul 14, 2008
Clinical News

Litx: Phase I/II start

...This quarter, Light Sciences will begin a dose-escalation, U.S. Phase I/II trial in 12 patients. Light Sciences Oncology Inc....
Read More
BioCentury | May 26, 2008
Finance

Ebb & Flow

...upcoming financings, or at least their interest in trying to get the next round completed. Light Sciences Oncology...
Read More
BioCentury | Apr 14, 2008
Company News

Light Sciences Oncology board of directors update

Light Sciences Oncology Inc. , Bellevue, Wash. Business: Cancer Appointed: David Holveck, president and CEO of Endo Pharmaceuticals Holdings Inc. WIR Staff cancer...
Read More
Items per page:
1 - 10 of 33
BioCentury | Mar 18, 2010
Distillery Therapeutics

Indication: Cancer

...includes synthesizing polymer conjugates of the compounds to improve their tumor delivery and photoactivation properties. Light Sciences Oncology Inc.'s...
Read More
BioCentury | Mar 8, 2010
Clinical News

Aptocine talaporfin sodium: Completed Phase III enrollment

...296 and 394 events, respectively. Light Sciences has an SPA from FDA for the trial. Light Sciences Oncology Inc....
Read More
BioCentury | Aug 24, 2009
Clinical News

Aptocine talaporfin sodium: Phase II started

...IV Aptocine followed by 100 J/cm of light delivered for 83 minutes in 40 patients. Light Sciences Oncology Inc....
Read More
BioCentury | Aug 17, 2009
Clinical News

Aptocine talaporfin sodium: Phase I started

...of light in 18-24 patients ages 18-34 with PN tumors that are not surgically resectable. Light Sciences Oncology Inc....
Read More
BioCentury | Dec 8, 2008
Clinical News

Litx: Completed Phase III enrollment

...of care treatments including radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and percutaneous ethanol injection (PEI). Light Sciences Oncology Inc....
Read More
BioCentury | Jul 16, 2008
Financial News

Light Sciences raises $40.1 million

Light Sciences Oncology (Bellevue, Wash.) raised $40.1 million in a series C round. Investors were not disclosed. Leerink acted as placement agent and financial advisor. Light Sciences is developing Light Infusion Therapy ( Litx ), a...
Read More
BioCentury | Jul 14, 2008
Clinical News

Litx: Phase IIa start

...This quarter, Light Sciences will begin an Australian Phase IIa trial in 40 patients. Light Sciences Oncology Inc....
Read More
BioCentury | Jul 14, 2008
Clinical News

Litx: Phase I/II start

...This quarter, Light Sciences will begin a dose-escalation, U.S. Phase I/II trial in 12 patients. Light Sciences Oncology Inc....
Read More
BioCentury | May 26, 2008
Finance

Ebb & Flow

...upcoming financings, or at least their interest in trying to get the next round completed. Light Sciences Oncology...
Read More
BioCentury | Apr 14, 2008
Company News

Light Sciences Oncology board of directors update

Light Sciences Oncology Inc. , Bellevue, Wash. Business: Cancer Appointed: David Holveck, president and CEO of Endo Pharmaceuticals Holdings Inc. WIR Staff cancer...
Read More
Items per page:
1 - 10 of 33